Dianthus Therapeutics, Inc. /DE/
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
DNTH$88.81-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(in thousands, except share data)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Other · Total | ||||||
| Common Stock · Additional · Accumulated · Comprehensive · Stockholders’ | ||||||
| Shares | Amount | Paid-in Capital | Deficit | Income/(Loss) | Equity | |
| Balance, December 31, 2024 | 31,115,341 | $31 | $526,732 | $(174,392) | $106 | $352,477 |
| Exercise of pre-funded warrants | 1,000,333 | 1 | — | — | — | 1 |
| Exercise of stock options | 3,321 | — | 31 | — | — | 31 |
| Issuance of common stock under employee stock purchase plan (“ESPP”) | 6,938 | — | 129 | — | — | 129 |
| Stock-based compensation expense | — | — | 5,315 | — | — | 5,315 |
| Net loss | — | — | — | (29,511) | — | (29,511) |
| Unrealized gain on marketable securities | — | — | — | — | 164 | 164 |
| Balance, March 31, 2025 | 32,125,933 | $32 | $532,207 | $(203,903) | $270 | $328,606 |
| Exercise of stock options | 50,549 | — | 568 | — | — | 568 |
| Stock-based compensation expense | — | — | 5,706 | — | — | 5,706 |
| Net loss | — | — | — | (31,629) | — | (31,629) |
| Unrealized loss on marketable securities | — | — | — | — | (172) | (172) |
| Balance, June 30, 2025 | 32,176,482 | $32 | $538,481 | $(235,532) | $98 | $303,079 |
| Issuance of common stock and pre-funded warrants in connection with public offering, net of issuance costs of $404 | 7,627,879 | 8 | 271,856 | — | — | 271,864 |
| Exercise of pre-funded warrants | 2,833,588 | 3 | (3) | — | — | — |
| Exercise of stock options | 204,751 | — | 2,229 | — | — | 2,229 |
| Issuance of common stock under ESPP | 11,863 | — | 188 | — | — | 188 |
| Stock-based compensation expense | — | — | 5,794 | — | — | 5,794 |
| Net loss | — | — | — | (36,765) | — | (36,765) |
| Unrealized gain on marketable securities | — | — | — | — | 65 | 65 |
| Balance, September 30, 2025 | 42,854,563 | $43 | $818,545 | $(272,297) | $163 | $546,454 |
| Balance, December 31, 2023 | 14,817,696 | $15 | $258,231 | $(89,423) | $47 | $168,870 |
| Issuance of common stock and pre-funded warrants in connection with the private placement, net of issuance costs of $14,665 | 14,500,500 | 14 | 215,319 | — | — | 215,333 |
| Exercise of stock options | 30,430 | — | 271 | — | — | 271 |
| Stock-based compensation expense | — | — | 2,035 | — | — | 2,035 |
| Net loss | — | — | — | (13,748) | — | (13,748) |
| Unrealized loss on marketable securities | — | — | — | — | (74) | (74) |
| Balance, March 31, 2024 | 29,348,626 | $29 | $475,856 | $(103,171) | $(27) | $372,687 |
| Exercise of stock options | 3,514 | — | 47 | — | — | 47 |
| Stock-based compensation expense | — | — | 3,101 | — | — | 3,101 |
| Net loss | — | — | — | (17,607) | — | (17,607) |
| Unrealized loss on marketable securities | — | — | — | — | (10) | (10) |
| Balance, June 30, 2024 | 29,352,140 | $29 | $479,004 | $(120,778) | $(37) | $358,218 |
| Exercise of stock options | 14,212 | — | 296 | — | — | 296 |
| Stock-based compensation expense | — | — | 3,840 | — | — | 3,840 |
| Net loss | — | — | — | (25,174) | — | (25,174) |
| Unrealized gain on marketable securities | — | — | — | — | 718 | 718 |
| Balance, September 30, 2024 | 29,366,352 | $29 | $483,140 | $(145,952) | $681 | $337,898 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.